Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma

Okeke, Constance; Burstein, Eitan; Trubnik, Valerie; Deom, J; Cooper, Michael S; Brinkley, Desirae A; Thimons, James; Kabiri, Alexander J; Gelb, Kerry M

doi:10.1007/s40123-020-00307-0

Cited by 13 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the patients in both studies had advanced glaucoma and the mean number of medications was similar (3.0 vs. 3.2), so the difference in efficacy is not easily explained. The present study’s data for LBN’s real-world efficacy in patients on multiple glaucoma medications, often with surgical histories, complement those of the Okeke study, which showed that LBN was effective specifically in treatment-naive eyes with a new glaucoma diagnosis 18…”

Section: Discussionsupporting

confidence: 63%

“…The present study's data for LBN's real-world efficacy in patients on multiple glaucoma medications, often with surgical histories, complement those of the Okeke study, which showed that LBN was effective specifically in treatment-naive eyes with a new glaucoma diagnosis. 18 LBN was well-tolerated, with a favorable safety profile, with only 8 patients (14%) reporting adverse effects and only 4 patients (7%) having LBN discontinued due to these adverse effects. Of note, there were 4 patients who were excluded from analysis because they had glaucoma surgery or laser during the study window.…”

Section: Discussionmentioning

confidence: 95%

“…LBN was introduced for clinical use in December 2017, following US FDA approval in October 2017. Since approval, a real-world retrospective study has been published asserting LBN’s efficacy in treatment-naive patients newly diagnosed with OAG or OHT 18. The present study takes a broader approach, assessing the first 2 years of use of LBN use in a real-world setting, in patients with mild to severe glaucoma who have not achieved sufficient IOP control with other agents or with laser or surgical interventions.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Radell

Sharma

Auyeung

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

We retrospectively reviewed records of patients prescribed latanoprostene bunod 0.024% (LBN) to assess its efficacy and safety in a real-world clinical setting. LBN was efficacious in lowering intraocular pressure (IOP) and had a favorable safety profile. Purpose:The aim of this study was to evaluate the usage of LBN, the first topical nitric oxide-donating prostaglandin analog (PGA) for reducing IOP, in clinical practice.Patients and Methods: Retrospective review identified patients prescribed LBN by 5 glaucoma specialists at an academic center from January 2018 to November 2019. Fifty-six patients (102 eyes) met inclusion criteria of an IOP measured at the visit LBN was prescribed and at 2 visits ≥ 7 days after beginning treatment, with no surgeries, lasers or medication changes during follow-up. Main outcome measures were IOP, number of ocular medications, and adverse effects.Results: IOP (mean ± SD, mm Hg) at the visit LBN was prescribed was 16.2 ± 4.3 on 3.2 ± 1.5 glaucoma medications. IOP at most recent visit was 13.7 ± 3.8 on 3.2 ± 1.6 medications. Mean IOP reduction was 2.1 ± 3.5 (P < 0.0001) at first follow-up, after 38.7 ± 36.5 days, and 2.5 ± 3.3 (P < 0.0001) at last follow-up, after 235.9 ± 160.8 days. Pressure decreased ≥ 2 mm Hg in 60%, ≥ 3 mm Hg in 46%, and ≥ 4 mm Hg in 34% of eyes. All patients received LBN as replacement for a PGA or latanoprost/netarsudil fixed-dose combination. Forty-three patients remained on LBN throughout the follow-up period. Seven were discontinued for insufficient pressure control, 4 for adverse effects including pain and itching, and 2 for financial reasons. Conclusions:In 2 years of clinical use of LBN, patients exhibited IOP reductions that were statistically significant overall and clinically meaningful in 60% of patients. LBN was well-tolerated and may be more efficacious than traditional PGAs.

show abstract

Section: Discussionsupporting

confidence: 63%

Section: Discussionmentioning

confidence: 95%

mentioning

confidence: 99%

See 1 more Smart Citation

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Radell

Sharma

Auyeung

et al. 2021

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

“…This is supported by studies that found LBN to have IOP-lowering effects on both naive eyes and eyes on multiple glaucoma medications. 18 , 21 …”

Section: Discussionmentioning

confidence: 99%

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma

Khouri¹,

Zhou²,

Bekerman³

2023

Journal of Current Glaucoma Practice

View full text Add to dashboard Cite

A bstract Aim To investigate the long-term efficacy of adjunctive use of latanoprostene bunod (LBN), a new nitric oxide donating prostaglandin medication, in refractory cases of glaucoma at a tertiary care center. Materials and methods A review for patients who received add-on LBN was conducted from 1 st January 2018 to 31 st August 2020. A total of 33 patients (53 eyes) met the inclusion criteria of being on ≥3 topical medications, having an intraocular pressure measurement prior to starting LBN, and having adequate follow-up. Baseline demographics, prior treatments, adverse effects, and intraocular pressures measured at baseline, 3, 6, and 12 months were recorded. Results Mean baseline intraocular pressure (IOP) [mm Hg ± standard deviation (SD)] was 19.9 ± 6.0. At 3 months, 49 eyes had a mean IOP of 17.3 ± 5.5 ( p < 0.01) with an absolute reduction of 2.6 ± 6.6 and a percent reduction of 9 ± 28%. At 6 months, 35 eyes had a mean IOP of 17.2 ± 4.7 ( p < 0.01) with an absolute reduction of 3.6 ± 7.4 and a percent reduction of 11 ± 30%. At 12 months, 28 eyes had a mean IOP of 16 ± 4.5 ( p < 0.01) with an absolute reduction of 5.8 ± 7.4 and a percent reduction of 19 ± 38%. Over the course of the study, 18 eyes were lost to follow-up. Three eyes had a laser trabeculoplasty, and four eyes required incisional surgery. No eyes discontinued the medication due to adverse effects. Conclusion Adjunctive use of LBN in refractory glaucoma showed clinically and statistically significant IOP reductions at 3, 6, and 12-month time points. IOP reduction in patients was stable throughout the course of the study, with the largest decreases seen at the 12-month interval. Clinical significance LBN was well tolerated by patients and may be useful as an additive agent in providing long-term intraocular pressure reduction for patients with severe glaucoma on maximal therapy. How to cite this article Zhou B, Bekerman VP, Khouri AS. Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma. J Curr Glaucoma Pract 2022;16(3):166-169.

show abstract

“…Randomized controlled trials (RCTs), such as APOLLO, JUPITER, LUNAR, VOYAGER, and CONSTELLATION, as well as a pooled study conducted by Weinreb et al, have assessed the IOP-reduction effect of LBN in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) [ 9 , 10 , 11 , 12 , 13 , 14 ]. Since the approval of LBN, retrospective studies (e.g., chart reviews) regarding its IOP-lowering effect in the real-world setting have been performed [ 15 , 16 , 17 ]. To ensure a complete understanding of LBN 0.024%, we investigated its efficacy in decreasing IOP in both the RCTs and retrospective studies.…”

Section: Introductionmentioning

confidence: 99%

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Chen

Hung

et al. 2022

JCM

View full text Add to dashboard Cite

Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.

show abstract

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma

Abstract: Introduction: The objective of this study was to evaluate real-world effectiveness of latanoprostene bunod (LBN) ophthalmic solution 0.024% in treatment-naïve patients newly diagnosed with open-angle glaucoma (OAG) or ocular hypertension.

Cited by 13 publications

References 40 publications

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Two-Year Experience With Latanoprostene Bunod in Clinical Practice

Use of Latanoprostene Bunod as Adjunctive Glaucoma Therapy in Refractory Glaucoma

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

Contact Info

Product

Resources

About